Meditope Receives BioLabs Golden Ticket Award From Sanofi to Advance Bioconjugation Technology Research

PASADENA, Calif., April 24, 2018 -- Meditope Biosciences, Inc., a biotechnology company developing novel antibody-based cancer products using its proprietary technology, today announced it has received a BioLabs Golden Ticket from Paris-based biopharmaceutical company, Sanofi, to fund Meditope’s lab space. The work will be conducted at BioLabs in San Diego, part of a national network of premium co-working facilities designed to help science-based startups go further faster on limited capital investment.

This award marks the start of a research collaboration between Sanofi and Meditope, under which Meditope will conduct preclinical evaluation programs utilizing the bioconjugation technology SnAP (Site-specific novel Antibody Platform) it has developed over the past five years.

"This is a milestone for Meditope,” said Stephanie Hsieh, CEO of the Pasadena-based biotech company. “Our Sanofi relationship, with support from BioLabs, will allow us to explore novel, disease-specific applications of our proprietary SnAP technology to further prove its flexibility, simplicity and power to create new therapeutic approaches.”

As a Gold sponsor, Sanofi is helping to fund Meditope’s residence in BioLabs’ fully equipped, world-class scientific facility through the Golden Ticket program. This investment supports membership in BioLabs and the cost of one year of bench space in BioLabs’ shared lab, including all of BioLabs’ shared infrastructure, programming and services. Potential areas for further scientific evaluation of Meditope’s bioconjugation technology SnAP may include diabetes, cardiovascular, immunology and oncology.   

“At BioLabs, one of our goals in establishing our innovation ecosystem is to ensure creative exchange happens formally and informally between our startups and sponsors — the Golden Ticket helps us toward that goal,” added Susie Harborth, co-founder, BioLabs San Diego, and COO, BioLabs. “We’re pleased to facilitate potential medical science breakthroughs.”

About Meditope Biosciences

Meditope Biosciences is a biotechnology company developing novel antibody-based cancer products using its SnAP technology (Site-specific novel Antibody Platform). Discovered at City of Hope, a National Cancer Institute designated Comprehensive Cancer Center, SnAP has the potential of turning any antibody into a proprietary, site-specific "LEGO-like" system that can attach and detach nearly anything to an antibody. Meditope's SnAP technology has the potential to advance the antibody market by producing an array of new therapeutic and diagnostic products. Visit www.meditope.com.

About BioLabs

A membership-based network of shared laboratory facilities located in key cities with proven biotech innovation clusters, BioLabs offers beautifully designed coworking environments that pair fully equipped and supported lab, office, and event spaces with relevant programming and unparalleled access to capital and industry partners. These fertile, supportive ecosystems allow young companies to shift their focus from startup operations to experimentation and innovation so they can reach their scientific potential quickly and achieve business success. Companies can start with a single lab bench and scale up as they grow. The expanding BioLabs network now comprises sites in Boston and Cambridge, Massachusetts; Durham, North Carolina; San Diego and San Francisco, California; New York City, and Princeton, New Jersey.

Media Contact:

Meditope Biosciences
PondelWilkinson Inc.
George Medici/Roger Pondel
310-279-5980
[email protected]; [email protected]

BioLabs
Caroline Grossman
781-771-5579
[email protected]